0001562180-19-005993.txt : 20191210
0001562180-19-005993.hdr.sgml : 20191210
20191210212604
ACCESSION NUMBER: 0001562180-19-005993
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20191209
FILED AS OF DATE: 20191210
DATE AS OF CHANGE: 20191210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: IGUCHI KIMI
CENTRAL INDEX KEY: 0001304815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 191278838
MAIL ADDRESS:
STREET 1: 100 FOXBOROUGH BOULEVARD
STREET 2: SUITE 240
CITY: FOXBOROUGH
STATE: MA
ZIP: 02035
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2019-12-09
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001304815
IGUCHI KIMI
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
CFO & Treasurer
Common Stock
2019-12-09
4
M
false
15000.00
1.36
A
28761.00
D
Common Stock
2019-12-10
4
M
false
500.00
1.36
A
29261.00
D
Stock Option (Right to Buy)
1.36
2019-12-09
4
M
false
15000.00
0.00
D
2024-01-22
Common Stock
15000.00
4047.00
D
Stock Option (Right to Buy)
1.36
2019-12-10
4
M
false
500.00
0.00
D
2024-01-22
Common Stock
500.00
3547.00
D
The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on March 12, 2016.
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
2019-12-10
EX-24
2
kimiiguchipoa2019.txt
KIMI IGUCHI POA 2019
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Erin Lanciani (SVP, People and
Organizational Strategy), and Jennifer Fitzpatrick (Vice President,
Corporate Counsel) for as long as they remain employees of Sage
Therapeutics, Inc., and Laurie Burlingame of Goodwin Procter, each
acting singly, or their successors in role, to take the following
actions, acting as my agent and attorney-in-fact, with full power of
substitution:
(1) to prepare and sign on my behalf any Form 3, Form 4 or
Form 5 pursuant to Section 16 of the Securities Exchange Act of 1934,
as amended, and to file the same with the Securities and Exchange
Commission, NASDAQ, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144
pursuant to the Securities Act of 1933, as amended, and to file the
same with the Securities and Exchange Commission, NASDAQ, NYSE, and
each stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by law;
and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am an executive officer
or director of Sage Therapeutics, Inc., and shall not be affected by
my subsequent disability or incompetence. I may revoke this Power of
Attorney by written notice delivered, in person or by nationally
recognized courier, to the attention of the SVP, General Counsel of
Sage Therapeutics, Inc.
/s/ Kimi Iguchi
___________________________________________________
(Signature of Executive Officer or Director)
Name: Kimi Iguchi, Chief Financial Officer
Date: 1/23/2019